Varda Space Industries
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries announced $251M in Series D financing on September 30, 2026. Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Round details
The financing includes backing from Lux Capital, Natural Capital, Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step. The company did not publish a valuation with the announcement.
- Round: Series D
- Capital announced: $251M
- Total funding reported: $598M
- Headquarters: El Segundo, CA
How the company plans to use the capital
Varda said the round gives it the resources to increase its cadence, deepen its pharmaceutical partnerships, and get closer to delivering the first medicine made in space.
Why this matters for GTM teams
Since its first mission launched in 2023, Varda has completed six successful reentry missions, with more than a dozen further launches and reentries planned through 2028, according to the announcement.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Varda Series D announcement.
Company Info
Investors (8)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Breye Therapeutics Raises €67.5M Series A for Oral Retinal Disease Drugs
Breye Therapeutics raised an over-subscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into a Phase 2 trial.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free